Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 42,001 shares at $60.05 ($2.6M) on 2021-03-02, disclosed to the SEC on 2021-03-03.
Open-market sale of $2.6M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.33 | 1,050 | $64K | 2.5% |
| 2 | $61.33 | 1,050 | $64K | 2.5% |
| 3 | $61.33 | 1,608 | $99K | 3.9% |
| 4 | $61.33 | 1,608 | $99K | 3.9% |
| 5 | $62.11 | 2,257 | $140K | 5.5% |
| 6 | $62.11 | 2,257 |
| $140K |
| 5.5% |
| 7 | $62.11 | 1,473 | $91K | 3.6% |
| 8 | $62.11 | 1,473 | $91K | 3.6% |
| 9 | $63.22 | 1,169 | $74K | 2.9% |
| 10 | $63.22 | 1,794 | $113K | 4.4% |
| 11 | $63.22 | 1,794 | $113K | 4.4% |
| 12 | $63.22 | 1,169 | $74K | 2.9% |
| 13 | $64.09 | 406 | $26K | 1.0% |
| 14 | $64.09 | 625 | $40K | 1.6% |
| 15 | $65.28 | 479 | $31K | 1.2% |
| 16 | $65.29 | 734 | $48K | 1.9% |
| 17 | $66.04 | 792 | $52K | 2.0% |
| 18 | $66.04 | 516 | $34K | 1.3% |
| 19 | $66.04 | 792 | $52K | 2.0% |
| 20 | $67.60 | 30 | $2K | 0.1% |
| 21 | $67.60 | 46 | $3K | 0.1% |
| 22 | $57.93 | 2,377 | $138K | 5.4% |
| 23 | $57.93 | 2,377 | $138K | 5.4% |
| 24 | $57.93 | 3,644 | $211K | 8.2% |
| 25 | $57.93 | 3,644 | $211K | 8.2% |
| 26 | $58.90 | 1,095 | $64K | 2.5% |
| 27 | $58.90 | 1,095 | $64K | 2.5% |
| 28 | $58.90 | 714 | $42K | 1.6% |
| 29 | $60.05 | 1,052 | $63K | 2.5% |
| 30 | $60.05 | 686 | $41K | 1.6% |
| 31 | $60.05 | 1,052 | $63K | 2.5% |
| 32 | $60.61 | 554 | $34K | 1.3% |
| 33 | $60.61 | 361 | $22K | 0.9% |
| 34 | $61.90 | 90 | $6K | 0.2% |
| 35 | $61.90 | 138 | $9K | 0.3% |
| Total | $60.92 avg | 42,001 | $2.6M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |